精神医学杂志
精神醫學雜誌
정신의학잡지
Journal of Psychiatry
2015年
4期
267-270
,共4页
苏磊%孙自豪%冯凡%李龙飞
囌磊%孫自豪%馮凡%李龍飛
소뢰%손자호%풍범%리룡비
利培酮微球%利培酮%精神分裂症
利培酮微毬%利培酮%精神分裂癥
리배동미구%리배동%정신분렬증
Risperidone long-acting injection%Risperidone%Schizophrenia
目的:探寻利培酮微球和利培酮治疗精神分裂症患者的疗效和安全性。方法将160例精神分裂症患者随机分为研究组和对照组各80例,研究组用利培酮微球系统治疗,对照组用利培酮系统治疗,共3个月,在基线和治疗后1、2、3个月末应用阳性和阴性综合征量表( PANSS)、临床疗效总评量表-病情严重程度( CGI-S)、临床疗效总评量表-疗效总评( CGI-I)、锥体外系症状评定量表( ESRS)评价。结果两组在治疗后第1、2、3个月末的PANSS评分均低于基线时相应评分(P<0.05)。在治疗后第2、3个月末,研究组PANSS评分以及CGI评分均低于对照组(P<0.05)。研究组治疗后第1、2、3个月末ESRS评分均低于对照组(P<0.05)。结论利培酮微球可有效、安全地治疗精神分裂症患者。
目的:探尋利培酮微毬和利培酮治療精神分裂癥患者的療效和安全性。方法將160例精神分裂癥患者隨機分為研究組和對照組各80例,研究組用利培酮微毬繫統治療,對照組用利培酮繫統治療,共3箇月,在基線和治療後1、2、3箇月末應用暘性和陰性綜閤徵量錶( PANSS)、臨床療效總評量錶-病情嚴重程度( CGI-S)、臨床療效總評量錶-療效總評( CGI-I)、錐體外繫癥狀評定量錶( ESRS)評價。結果兩組在治療後第1、2、3箇月末的PANSS評分均低于基線時相應評分(P<0.05)。在治療後第2、3箇月末,研究組PANSS評分以及CGI評分均低于對照組(P<0.05)。研究組治療後第1、2、3箇月末ESRS評分均低于對照組(P<0.05)。結論利培酮微毬可有效、安全地治療精神分裂癥患者。
목적:탐심리배동미구화리배동치료정신분렬증환자적료효화안전성。방법장160례정신분렬증환자수궤분위연구조화대조조각80례,연구조용리배동미구계통치료,대조조용리배동계통치료,공3개월,재기선화치료후1、2、3개월말응용양성화음성종합정량표( PANSS)、림상료효총평량표-병정엄중정도( CGI-S)、림상료효총평량표-료효총평( CGI-I)、추체외계증상평정량표( ESRS)평개。결과량조재치료후제1、2、3개월말적PANSS평분균저우기선시상응평분(P<0.05)。재치료후제2、3개월말,연구조PANSS평분이급CGI평분균저우대조조(P<0.05)。연구조치료후제1、2、3개월말ESRS평분균저우대조조(P<0.05)。결론리배동미구가유효、안전지치료정신분렬증환자。
Objective To explore the efficacy and safety of risperidone long-acting injection and risperidone in treatment for patients with schizophrenia.Methods A total of 160 patients with schizophrenia were randomly divided into study group ( 80 cases) with risperidone long-acting injection and control group(80 cases) with risperidone for treatment of 3 months.They were assessed with Positive and Negative Syndrome Scale(PANSS), Clinical Global Impression-Severity of Illness(CGI-S), Clinical Global Impression-Global Improvement(CGI-I) and Extrapyramidal Symptom Rating Scale(ESRS) at baseline , 1st month end, 2nd month end and 3rd month end of treatment.Results At 1st month end, 2nd month end and 3rd month end of treatment, the factors and total scores of PANSS in two groups were all significantly lower than those at baseline(P<0.05).At 2nd month end and 3rd month end of treatment, the factors and total scores of PANSS and CGI in study group were all significantly lower than those in control group(P<0.05).At 1st month end, 2nd month end and 3rd month end of treatment, the scores of ESRS in study group were significantly lower than those in control group(P<0.05).Conclusion It’s effective and safe for risperidone long-acting injection to treat the patients with schizophrenia.